Sarcopenia
Conditions
Brief summary
Sarcopenia represents the loss of skeletal muscle and strength that occurs with aging. It is a major component of frailty and its effect on daily functioning, falls, and fractures has been well documented. Along with the population aging worldwide, the number of people with sarcopenia is expected to increase and, thus, contributing to dependency and the anticipated increase in health and social care costs. The cause of sarcopenia is multifactorial. Recent evidence suggests that some reversibility exists, highlighting the importance of intervention modalities. However, the role of nutritional supplementation and exercise programs, either individually or in combination, is still uncertain, and further randomized controlled trials (RCTs) have been recommended by the International Sarcopenia Initiative. Therefore, the investigators plan to conduct a 24-month RCT to compare the effectiveness of 12-week exercise program alone, combined exercise program and nutrition supplement, and non-exercise control group on improving muscle mass, strength and power and physical performance in Chinese older people who have sarcopenia defined using the Asian Working Group Criteria (AWGC). The investigators hypothesize that compared with the non-exercise control group, there will be improvement in muscle strength, power and mass, and physical performance in the exercise alone group, and that there will be an additive effect with the combined exercise and nutrition supplement group. Chinese older people aged 65 years and over will be recruited for a brief screening of sarcopenia and cognitive status. Potential subjects will further undertake detailed body composition and biochemical measurements to check for their eligibility. Eligible subjects will be randomized to one of the three groups: exercise program alone, combined exercise program and nutrition supplement, or waitlist control group with the same exercise program offered after 24-week of study enrollment. Each group will have 45 subjects. Outcome measurements including muscle strength, power and mass, physical performance, instrumental activities of daily living and related biochemical measurements will be made at baseline, 12 and 24 weeks.
Interventions
BEHAVIORALExercise program alone
DIETARY_SUPPLEMENTCombined exercise program and nutrition supplement
Sponsors
Chinese University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Chinese origin * Normally reside in Hong Kong * Could speak and understand Chinese * With handgrip strength less than 26 kg for men and 18 kg for women and/or usual gait speed less than or equal to 0.8 m/s, as recommended by the Asian Working Group on Sarcopenia (AWGS) * With height-adjusted appendicular skeletal muscle mass (ASM/ht2) measured using dual X-ray absorptiometry (DEXA) less than 7.0 kg/m2 for men and 5.4 kg/m2 for women, as recommended by the AWGS * Willing to follow the study procedures
Exclusion criteria
* Recent (i.e. past 3 months) or concurrent participation in any clinical trial or dietary and/or exercise intervention program * Self-reported allergy to the ingredients of the nutrition supplement * Use of medications that could affect study outcomes * With cancer conditions that are currently undergoing treatment * Poorly controlled or unstable chronic obstructive pulmonary disease * Poorly controlled or unstable cardiovascular disease or diabetes or hypertension * Recent unhealed bone fracture (within the past 12 months) * With medical advice or conditions prohibiting exercise or medical conditions that precluded safe participation in an exercise program * With any other indication of a major medical or psychological illness, as judged by the investigators as ineligible to participate the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in gait speed | baseline, 12 weeks | This outcome will be measured using the 6-meter walk test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Handgrip strength | baseline, 12 weeks | Handgrip strength will be measured using a dynamometer |
| Bilateral leg extensors strength | baseline, 12 weeks | Bilateral leg extensors strength will be measured by spring gauge while seated, and the average value between right and left will be used for analysis. |
| Muscle power in the upper extremities | baseline, 12 weeks | This outcome will be measured using seated 1.8kg medicine ball throw test (maximum throw distance achieved in 3 trials). |
| Muscle power in the lower extremities | baseline, 12 weeks | This outcome will be measured using 5-chair stand test (time to complete standing from a chair 5 times as quickly as possible). |
| Height-adjusted appendicular skeletal muscle mass | baseline, 12 weeks | This outcome will be measured using dual X-ray absorptiometry (DEXA) |
| Improvement in sarcopenia category | baseline, 12 weeks | This outcome will be measured using DEXA |
| Health-related quality of life | baseline, 12 weeks | This outcome will be measured using validated Chinese version of short form (SF)-12 |
| Instrumental Activities of Daily Living (IADL) | baseline, 12 weeks | Participants will be asked to self-report of any impairment in walking two to three blocks outdoors on level ground, climbing 10 steps without resting, preparing own meals, doing heavy housework like scrubbing floors or washing windows, and shopping for groceries or clothes. A summed score from 0 to 5 was calculated from these activities as the degree of impairment in IADLs, with higher score indicating greater impairment. |
| Cardiorespiratory fitness | baseline, 12 weeks | Cardiorespiratory fitness will be measured by 6-minute walk test (6MWT). 6MWT will be completed and scored as the total number of meters walked in 6 minutes. |
| Serum cystatin C measurement measured using immunoassay method | baseline, 12 weeks | For combined exercise program and nutrition supplement group only |
| Renal function test measured by University Pathology Service | baseline, 12 weeks | For combined exercise program and nutrition supplement group only |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in gait speed | 12 weeks, 24 weeks | This outcome will be measured using the 6-meter walk test |
| Handgrip strength | 12 weeks, 24 weeks | Handgrip strength will be measured using a dynamometer |
| Bilateral leg extensors strength | 12 weeks, 24 weeks | Bilateral leg extensors strength will be measured by spring gauge while seated, and the average value between right and left will be used for analysis. |
| Muscle power in the upper extremities | 12 weeks, 24 weeks | This outcome will be measured using seated 1.5kg medicine ball throw test (maximum throw distance achieved in 3 trials). |
| Muscle power in the lower extremities | 12 weeks, 24 weeks | This outcome will be measured using 5-chair stand test (time to complete standing from a chair 5 times as quickly as possible). |
| Height-adjusted appendicular skeletal muscle mass | 12 weeks, 24 weeks | This outcome will be measured using DEXA |
| Improvement in sarcopenia category | 12 weeks, 24 weeks | This outcome will be measured using DEXA |
| Health-related quality of life | 12 weeks, 24 weeks | This outcome will be measured using validated Chinese version of SF-12 |
| Instrumental Activities of Daily Living | 12 weeks, 24 weeks | Participants will be asked to self-report of any impairment in walking two to three blocks outdoors on level ground, climbing 10 steps without resting, preparing own meals, doing heavy housework like scrubbing floors or washing windows, and shopping for groceries or clothes. A summed score from 0 to 5 was calculated from these activities as the degree of impairment in IADLs, with higher score indicating greater impairment. |
| Cardiorespiratory fitness | 12 weeks, 24 weeks | Cardiorespiratory fitness will be measured by 6-minute walk test (6MWT). 6MWT will be completed and scored as the total number of meters walked in 6 minutes. |
| Fasting blood samples for genetic study of genes related to physical function, sarcopenia and frailty | baseline, 12 weeks | — |
Countries
China
Outcome results
None listed